

From Department of Laboratory Medicine,
Division of Clinical Pharmacology,
Karolinska Institutet, Stockholm, Sweden

**IMPORTANCE OF
PHARMACOGENETIC AND
ENVIRONMENTAL FACTORS
FOR VARIATION IN
CAFFEINE DISPOSITION:
WITH SPECIAL EMPHASIS
ON CYP1A2, CYP2A6, NAT2
AND XO**

Natasa Djordjevic



**Karolinska
Institutet**

Stockholm 2012

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet. Printed by Universitetservices US-AB

© Djordjevic Natasa, 2012

ISBN 978-91-7457-681-8

ABSTRACT

Inter-individual variation in response to drugs conveys considerable risk of either therapy failure or drug toxicity. Caffeine, as one of the most frequently used psychoactive substances in the world, is not an exception, and both lack of effects and adverse reactions have been observed after usual doses. In addition to inter-individual differences at the drug-receptor level and drug-drug interactions, variability in caffeine metabolism has been proposed as a possible explanation. The objective of this study was to investigate the influence of pharmacogenetic and environmental factors, which are known to be of importance for inter-individual variation in drug disposition, on the activity of enzymes involved in caffeine metabolism, namely cytochrome P450 1A2 (CYP1A2) and 2A6 (CYP2A6), *N*-acetyltransferase-2 (NAT2) and xanthine oxidase (XO).

The study involved unrelated healthy volunteers from three ethnically distinct populations: Serbian (n=140), Swedish (n=190) and Korean (n=150). Phenotyping of CYP1A2, CYP2A6, NAT2 and XO was performed using caffeine as a probe drug and measuring concentration of parent compound and its metabolites in plasma or urine samples. CYP1A2 activity was estimated by 17X/137X plasma ratio, and CYP2A6, NAT2 and XO activities were determined by 17U/17X, AFMU/(AFMU+1X+1U) and 1U/(1U+1X) urinary ratios, respectively. In addition, subjects were genotyped for the most important *CYP1A2*, *CYP2A6* and *NAT2* polymorphisms.

Daily consumption of at least three cups of coffee in non-OC (oral contraceptive) users significantly increased CYP1A2 enzyme activity in both Swedes ($P < 0.0001$) and Serbs ($P = 0.0002$). When additionally controlling for smoking, the observed difference remained significant in both populations ($P \leq 0.02$). Significant association of heavy coffee consumption with high CYP1A2 enzyme activity was observed only in carriers of -163 A/A, and increasing effect of -163C>A on CYP1A2 inducibility was found in both Serbian ($P = 0.022$) and Swedish ($P = 0.016$) nonsmoking heavy coffee consumers. There was no significant difference in CYP1A2 enzyme activity among genotypes in non-heavy coffee consumers. Controlling for the effect of smoking, heavy coffee consumption habit and OC use, significantly lower 17X/137X ratio was observed in Serbs than in Swedes ($P = 0.0003$). Comparison between Swedes and Koreans revealed that functional *CYP2A6* alleles were more frequent in former, whereas the defective were more frequent in latter ($P \leq 0.002$). *CYP2A6* genotype significantly affected enzyme activity in both populations ($P = 0.004$), while no effect of sex, age, cigarette smoking or OC use was observed. CYP2A6 activity was higher in Swedes compared to Koreans, with 3.16% of Swedes and 18.75% of Koreans being slow metabolizers ($P = 0.0001$). The observed differences between the two populations remained significant when controlling for the genotype effect, i.e. within rapid ($P = 0.0007$) and intermediate ($P = 0.04$) genotype groups. Rapid acetylator was the predominant NAT2 phenotype in Serbs, present in 55% of the population. Significant NAT2 genotype-phenotype association was detected in Serbs ($P < 0.0001$), Swedes ($P = 0.03$) and Koreans ($P = 0.008$). Partial NAT2 genotype-phenotype discordance in Serbian rapid acetylators could not be explained by *NAT1* gene polymorphism. Koreans displayed significantly

higher NAT2 activity compared to Swedes, and the difference remained significant when controlling for the influence of cigarette smoking, sex, or OC use ($P < 0.0001$), as well as NAT2 genotype ($P = 0.016$). Swedes and Koreans significantly differed in terms of NAT2 genotype groups distribution ($P < 0.0001$). Stratified by genotype, among carriers of at least one wild type NAT2*4 allele Koreans displayed higher enzyme activity compared to Swedes ($P = 0.004$). No significant influence of smoking or sex on NAT2 activity was observed in Serbs, Swedes or Koreans. OC use significantly increased NAT2 activity in Swedish women ($P = 0.007$). In terms of XO activity, no significant difference between Swedes and Koreans was detected. In Swedes, higher XO activity was observed in women compared to men ($P = 0.003$), and the effect remained significant after controlling for OC use ($P = 0.01$). OC use and cigarette smoking did not affect XO activity in either Swedes or Koreans.

In conclusion, habitual heavy coffee consumption induces CYP1A2 enzyme activity in carriers of CYP1A2 -163 A/A genotype. CYP2A6 genotype, but not sex, age, cigarette smoking and OC use, significantly affect CYP2A6 enzyme activity. NAT2 genotype, but not sex and cigarette smoking, significantly affect NAT2 enzyme activity. Cigarette smoking and OC use do not affect XO enzyme activity. In Swedes, female sex and oral contraceptive use are associated with higher XO and NAT2 enzyme activities, respectively. Swedes display significantly higher CYP1A2 and CYP2A6 activities compared to Serbs and Koreans, respectively. Koreans display significantly higher NAT2 enzyme activity compared to Swedes. Serbs differ from other Caucasians in terms of *N*-acetylation capacity, due to unprecedented high prevalence of rapid acetylator phenotype. There is no inter-ethnic difference between Swedes and Koreans in terms of XO enzyme activity.

LIST OF PUBLICATIONS

- I. **Djordjevic N**, Ghotbi R, Jankovic S, Bertilsson L, Aklillu E. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. *Eur J Clin Pharmacol* 2008; 64(4): 381-5.
- II. **Djordjevic N**, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. *Eur J Clin Pharmacol* 2010; 66(7):697-703.
- III. **Djordjevic N**, Carrillo JA, Ueda N, Gervasini G, Fukasawa T, Suda A, Jankovic S, Aklillu E. N-acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a white population. *J Clin Pharmacol* 2011; 51: 7: 994-1003.
- IV. **Djordjevic N**, Carrillo JA, Roh HK, Karlsson S, Ueda N, Bertilsson L, Aklillu E. Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. *J Clin Pharmacol* 2011; DOI: 10.1177/0091270011420261
- V. **Djordjevic N**, van den Broek MPJ, Carrillo JA, Roh HK, Bertilsson L, Aklillu E. Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. In manuscript.

CONTENTS

1	Introduction	1
1.1	Variation in drug disposition.....	1
1.1.1	Pharmacogenetics.....	1
1.1.2	Environmental factors.....	2
1.2	Caffeine.....	2
1.2.1	CYP1A2	5
1.2.2	CYP2A6	5
1.2.3	NAT2.....	6
1.2.4	XO	7
2	Objectives	9
3	Materials and methods	10
3.1	Subjects.....	10
3.2	Study design	10
3.3	Laboratory analyses.....	11
3.3.1	Genotyping.....	11
3.3.2	Phenotyping.....	13
3.4	Statistical analyses.....	14
3.5	Ethical considerations.....	15
4	Results	16
4.1	CYP1A2.....	16
4.2	CYP2A6.....	16
4.3	NAT2	17
4.4	XO.....	18
5	Discussion.....	19
5.1	CYP1A2.....	19
5.2	CYP2A6.....	21
5.3	NAT2	22
5.4	XO.....	24
6	Conclusions	26
7	Acknowledgements.....	27
8	References	28

LIST OF ABBREVIATIONS

CYP1A2	Cytochrome P450 1A2
CYP2A6	Cytochrome P450 2A6
NAT2	N-acetyltransferase-2
XO	Xanthine oxidase
137X	Caffeine (1,3,7-trimethylxanthine)
17X	Paraxanthine (1,7-dimethylxanthine)
17U	1,7-dimethyluric acid
AFMU	5-acetylamino-6-formylamino-3-methyluracil
1X	1-methylxanthine
1U	1-methyluric acid
OC	Oral contraceptive
PCR	Polymerase chain reaction
RFLP	Restriction fragment length polymorphism
AS	Allele specific
SNP	Single nucleotide polymorphism
HPLC	High performance liquid chromatography
bp	Base pair
AHR	Aryl hydrocarbon receptor
ARNT	Aryl hydrocarbon receptor nuclear translocator
PAHs	Polycyclic aromatic hydrocarbons
XRE	Xenobiotic response element

1 INTRODUCTION

1.1 VARIATION IN DRUG DISPOSITION

Inter-individual variability in response to drugs represents an important problem in clinical practice, as it conveys considerable risk of either lack of efficacy or development of adverse effects and toxicity in patients on generally accepted and recommended therapy regimen (1-3). This could be due to the differences in drug disposition, i.e. pharmacokinetics (absorption, distribution, metabolism and elimination), in drug pharmacodynamics, which is related to drug target, or both (4, 5). Although all drugs exhibit certain variability, the highest potential for clinically significant event is observed in those with narrow therapeutic range and extensive metabolism (4-6).

To ensure maximal efficacy and safety of drug therapy, physicians need to choose and prescribe an appropriate medication at the right dose for each patient (5, 7). Due to inter-individual variability in drug disposition and response, numerous factors, classified as either intrinsic or extrinsic, have to be taken into account. Typical intrinsic factors are related to the individual, and include body weight, age, gender, concomitant diseases, and genetics. On the other hand, typical extrinsic factors are related to the environment that the individual is exposed to, including concomitant drug use, dietary intake, as well as exposure to certain substances such as tobacco and alcohol (3, 4, 8-10).

Although recognized as building bricks of inter-individual differences, certain intrinsic and extrinsic factors could be shared among individuals, assembling them into populations that differ among each other in terms of drug disposition and response (11, 12). Populations that share “common traits and customs”, such as genetic heritage, social background and environment, are regarded as ethnic populations (13, 14). Therefore, ethnicity has been accepted as a multidimensional determinant of described inter-individual variability (3, 9, 14-16).

Swedes belong to Scandinavian i.e. northern European population and live on the eastern side of the Scandinavian Peninsula, located at the far north of the Europe (17, 18). Serbs belong to the South Slavic Europeans that primarily inhabit central and western part of the Balkan Peninsula, known as the gate between the Europe and the Near East (19-21). Both Swedish and Serbian populations belong to Caucasians (20, 22). On the other hand, Korean population belongs to Asians and populates Korean Peninsula, which extends toward the south from the east part of the Asian continent (22, 23).

1.1.1 Pharmacogenetics

Genetic polymorphisms are naturally existing variants of the gene that are present in at least 1% of the population (24). Three major types of genetic polymorphisms are single nucleotide polymorphisms (SNPs), insertions/deletions (indels), and copy number variations (CNVs). Their functional effects depend on their localization within the gene or its flanking regions, and range from complete lack of protein production to induction of gene expression (5, 25). It has been estimated that up to 95% of inter-individual variability in drug disposition and response could be explained by genetic

polymorphisms alone, or by its interaction with other intrinsic and extrinsic factors (24).

Genetics can affect efficacy and safety of any drug whose pharmacokinetics or pharmacodynamics are regulated by proteins encoded by polymorphically expressed genes (6, 8, 24). Nevertheless, probably the most important source of phenotypically evident genetic variability lies within drug metabolizing enzymes that control phase I or phase II reactions (5-8, 25). Depending on the existing variants of the metabolizing enzyme coding gene, resulting phenotype can range from poor metabolizer, which can cause drug accumulation and toxicity, to ultrarapid metabolizer, leading to fast drug elimination and likely failure of the therapy (6, 10). The science that deals with the role of genetics in drug response is called pharmacogenetics (6).

1.1.2 Environmental factors

To date, numerous environmental factors influencing drug disposition and response have been identified, including nutrition components, cigarette smoking, alcohol, drugs and herbal products, as well as different xenobiotics present in food, water, soil or air, such as polycyclic aromatic hydrocarbons, dioxins, organic solvents, and organophosphate insecticides (26). Environmental factors may interact with drugs at different levels, increasing or decreasing their activity or toxicity. Yet, the most common interactions involve drug metabolizing enzymes and result in metabolism induction or inhibition (5).

The mechanism behind enzyme induction involves enhanced synthesis by activation of ligand-regulated transcription factors (e.g. induction of CYP1A2 by cigarette smoking) (27), or enzyme stabilization following transcription (e.g. induction of CYP2E1 by alcohol intake) (28). On the other hand, enzyme inhibition refers to competition for the enzyme's active site (e.g. inhibition of CYP3A4 by indinavir) (29), or binding to a separate site on the enzyme or to enzyme-substrate complex, making the enzyme nonfunctional (e.g. inhibition of CYP3A4 by erythromycin) (26). The clinical consequences of metabolism induction or inhibition by environmental factors range from therapeutic failure to adverse drug effects and drug toxicity (30).

1.2 CAFFEINE

Caffeine (1,3,7-trimethylxanthine) is an alkaloid naturally present in seeds, leaves or fruit of plants such as coffee (*Coffea sp.*), tea (*Camellia sinensis*), cocoa (*Theobroma cacao*), kola (*Cola acuminata*), yerba mate (*Ilex paraguariensis*), and guarana (*Paullinia cupana*) (31). History of caffeine use dates back thousands of years: first tea consumption has been attributed to Chinese emperor Shen Nung and his accidental discovery of the drink in 2737 B.C, while indulging in coffee originates from Ethiopia and is credited to goat herder Khaldi, who lived around 850 A.D (32-34). Not until 16th and 17th century caffeine consumption became widespread, yet today it represents one of the most frequently used psychoactive substances in the world (35). Variety of common beverages, products containing cocoa or chocolate, as well as certain medications, contains caffeine (31, 35, 36). Nevertheless, its primary source is coffee, delivering approximately 70% of all consumed caffeine to about one-third of the world population on a daily basis (34, 37).

Caffeine acts through multiple mechanisms, including inhibition of phosphodiesterase and blockade of γ -aminobutyric acid (GABA) receptors, but its competitive antagonism of adenosine effects is the most important at typical plasma concentrations (32, 36, 38, 39). Adenosine is an endogenous purine nucleoside that at physiological levels preferentially activates its A₁ and A_{2A} receptors, primarily localized in the brain (32, 40-42). Blockade of both A₁ and A_{2A} receptors prevents adenosine-induced GABA inhibition of dopaminergic system and increases the release of various neurotransmitters, and it is responsible for stimulating effects of caffeine (35, 40, 42).

In moderate doses, caffeine increases vigilance, endurance and neuromuscular coordination, improves mood and cognitive performance and decreases anxiety and fatigue (32, 35, 38, 39, 41, 43). In addition, it elevates circulating catecholamine levels and basal metabolism, promote lipolysis and help in weight loss, while in sensitive individuals may even raise systolic blood pressure (32, 35, 42). In clinical practice, caffeine is used as an analgesic in combination with aspirin, acetaminophen, codeine or ergotamine, but also as a short-term treatment of neonatal apnea of prematurity (44). With chronic caffeine use, the tolerance to its effects can develop within hours or days, and the reason is considered to be upregulation of A₁ receptors (32, 39). When the regular consumption of coffee is discontinued, the same mechanism causes the caffeine withdrawal syndrome, characterized by headache and fatigue as the most prominent symptoms, followed by irritability, nausea and vomiting. Withdrawal symptoms typically begin at 12-24 hours and peak at 20-48 hours after cessation of caffeine consumption, disappear within the three days after the last caffeine dose, but may persist for a week (32, 35, 40, 41, 43).

Very high doses of caffeine could lead to tachycardia, nausea, anxiety, restlessness and tremors (42), while the acute toxic dose of caffeine in adults has been estimated to approximately 10 grams per day (32, 42). On the other hand, moderate daily consumption of up to 400 mg of caffeine, except in childhood and pregnancy, should pose no risks to human health. Furthermore, beneficial effects of regular caffeine intake, including prevention of Parkinson's disease, diabetes mellitus or skin cancer, have been discovered (39, 42). However, not everyone respond to caffeine as described, so both lack of effects and adverse reactions have been observed after usual doses. In addition to inter-individual differences at the drug-receptor level and drug-drug interactions, variability in caffeine pharmacokinetics has been proposed as a possible explanation (1, 35).

Pharmacokinetics of caffeine has been widely investigated, and its basic principles are already well known. After ingestion, caffeine undergoes rapid and complete absorption from the gastrointestinal tract, reaching 100% bioavailability and the peak plasma level between 30 and 75min (31, 36). Due to its lipophilic properties and low plasma protein binding, caffeine easily penetrates all biologic membranes, including placental and blood-brain barrier (32, 38). It has an average half-life of about 4 to 6 hours and a total clearance of approximately 2ml/min/kg (36, 38). Only 2-3% of ingested dose is excreted unchanged in urine (36, 45). Metabolism of caffeine exhibits linear pharmacokinetics, which becomes saturated at doses higher than 250mg. It is mainly restricted to liver, and involves several drug-metabolizing enzymes, including

cytochrome P450 1A2 and 2A6, *N*-acetyltransferase-2 and xanthine oxidase (45-49) (Figure 1). Since it is safe and inexpensive, with rapid and complete absorption and metabolism short half-life, caffeine is considered an ideal probe drug for estimation of *in vivo* activity of these enzymes (47).




Figure 1. Caffeine metabolism in humans.

1.2.1 CYP1A2

Cytochrome P450 1A2 (CYP1A2) is an important phase I hepatic enzyme that metabolizes various endogenous substrates, such as steroid hormones, arachidonic acid and melatonin, and activates several procarcinogens, e.g. arylamines and aflatoxin B₁. Moreover, it is involved in biotransformation of more than 100 clinically used drugs, including antipsychotics clozapine, olanzapine and haloperidol, antidepressants amitriptyline and imipramine, sedative diazepam, analgesic acetaminophen, cardiovascular drugs propranolol, verapamil, anticoagulant warfarin, as well as theophylline and caffeine (48, 50-52).

CYP1A2 gene is located on chromosome 15 (15q22 – q24), spans about 7.8 kb and comprises 7 exons (50, 53). To date, numerous variations of *CYP1A2* gene have been reported (<http://www.cypalleles.ki.se/cyp1a2.htm>). However, only few of them have been associated with alteration in enzyme activity: substitution C>A at position –163 (rs762551), which tags *CYP1A2*1F* allele, leads to increased enzyme inducibility (54), while carriers of *CYP1A2*1C* (–3860G>A, rs2069514) display decreased CYP1A2 activity (55). Single nucleotide polymorphism (SNP) -163C>A represents common *CYP1A2* polymorphism, observed at 60-70% frequency in many Caucasian, Asian and African populations (27, 56, 57). On the other hand, –3860G>A was found to be mainly present in Asia (the frequency of about 25%), while it is extremely rare in other populations (27, 56, 57).

CYP1A2 activity has been reported to vary significantly among individuals, resulting in up to 40-fold difference in steady-state plasma concentration of substrate (52, 58). This wide variation has been attributed to either genetic or environmental factors (58). It has been shown that 42, 38, and 33% of the catalytic activity, protein expression, and mRNA levels, respectively, seem to be due to genetic variation of CYP1A2 (52). Environmental factors of influence include cigarette smoking (27), charcoal-grilled meat (59), omeprazole (56) and carbamazepine (60) as inducers, and oral contraceptives (27), fluvoxamine (61) and fluoroquinolone antibiotics (52) as inhibitors. Investigations of gender difference in CYP1A2 activity (27, 62, 63) or possible influence of caffeine consumption (63, 64) gave inconclusive results. Inter-ethnic differences in CYP1A2 activity have been reported as lower enzyme activity in black compared to white populations (62, 65).

As the metabolism of caffeine is more than 90% dependent on CYP1A2 (transformation of caffeine into its main metabolite 17X), its clearance is considered the standard probe for assessment of CYP1A2 activity (48, 52, 58). Many urine caffeine metabolic ratios, such as (17X+17U)/137X (66) and (AFMU+1X+1U)/17U (64), have been used, but plasma or saliva 17X/137X ratio has been suggested as the most appropriate for estimation of *in vivo* CYP1A2 activity (46, 67, 68).

1.2.2 CYP2A6

Cytochrome P450 2A6 (CYP2A6) is another phase I metabolizing enzyme, expressed mainly in the liver, which is important for metabolism of steroids and fatty acids and activation of procarcinogenes (e.g. nitrosamines and aflatoxin B₁). In addition, it plays

an essential role in biotransformation of certain drugs, including antiepileptic valproic acid, anesthetics halothane and methoxyflurane, aldehyde dehydrogenase inhibitor disulfiram, chemotherapeutic drugs cyclophosphamide, iphosphamide and tegafur, well as nicotine and caffeine (50, 69-72).

CYP2A6 gene has been mapped to chromosome 19 (19q12 – q13.2), spans a region of about 6 kb and comprises 9 exons (69), and it is highly polymorphic (<http://www.cypalleles.ki.se/cyp2a6.htm>). Many of the described variants are nonsynonymous, e.g. *CYP2A6**4 (gene deletion) and *CYP2A6**5 (1436G>T, rs5031017) completely lack enzyme activity, *CYP2A6**7 (1412T>C, rs5031016), *CYP2A6**8 (1454G>T, rs28399468) and *CYP2A6**9 (-48T>G, rs28399433) decrease *CYP2A6*, while *CYP2A6* duplication corresponds to the presence of three copies of the gene and thus provides about 1.4-fold higher enzyme activity (73-77).

Wide inter-individual variations in *CYP2A6* activity (more than 100-fold) that have been observed seem to be affected by a variety of factors (69, 72). It has been shown that certain drugs, including rifampicin, dexamethasone, phenobarbital and oral contraceptives (50), act as inducers, whereas liver diseases, such as viral hepatitis A or alcohol-induced cirrhosis (69), as well as consumption of grapefruit juice and intake of ketokonazole (50, 78, 79), decrease *CYP2A6* activity. Several previous studies described inhibitory effect of cigarette smoking on *CYP2A6* enzyme activity (80, 81), while some researchers (82, 83), but not all (84, 85), reported sex as a factor of influence. Nevertheless, genetic polymorphisms of the *CYP2A6* gene are considered the major cause for the observed inter-individual variability of *CYP2A6* enzyme activity (69, 75, 86). Pronounced inter-ethnic variations in *CYP2A6* activity and expression have been observed as well, usually due to the well-known difference in the frequency of *CYP2A6* alleles among populations (69).

In the metabolism of caffeine, *CYP2A6* participates in the hydroxylation of the caffeine metabolite 17X to yield 17U (48). Due to its favorable pharmacokinetics properties and proven safety, caffeine test is considered valid and useful method for estimation of *in vivo* *CYP2A6* activity (72, 84). To assess enzymatic activity of *CYP2A6*, urinary metabolic ratios $17U/(17U+17X/137X+1U+1X+AFMU)$ (85) or $17U/17X$ (87) have been used successfully.

1.2.3 NAT2

Arylamine *N*-acetyltransferase 2 (NAT2) is a phase II enzyme with predominant localization in the liver, where it participates in metabolism of many xenobiotics (88). Substrates for NAT2 include commonly used drugs, such as antibacterials isoniazid, sulfamethoxazole and dapsone, chemotherapeutic drug aminoglutethimide, antiarrhythmic procainamide, anti-inflammatory drug 5-aminosalicylic acid, antihypertensives hydralazine and acebutolol, MAO inhibitor phenelzine, as well as caffeine (89-93). In addition, it metabolizes several environmental toxicants, including potentially carcinogenic heterocyclic amines present in well-cooked red meat and cigarette smoke (92).

NAT2 gene is located on chromosome 8 (8p21.3-23.1) and consists of one intronless open reading frame of 870 bp (92-94). More than 60 variant alleles of *NAT2* gene have been identified so far (http://louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-acetyltransferase-genenomenclature/nat_pdf_files/Human_NAT2_alleles.pdf/view). The presence of at least one wild-type *NAT2**4 or variant *11 (481C>T, rs1799929), *12 (803A>G, rs1208), *13 (282C>T, rs1041983) and *18 (845A>C, rs56054745) allele provides normal enzyme activity (92, 95). The rest of the *NAT2* allelic variants usually share one or more common missense single nucleotide polymorphisms, resulting in decreased expression, low activity, or enzyme instability (89, 92, 95).

Wide range of *N*-acetylation activity has been observed, classifying individuals as slow, intermediate, or rapid acetylators (92, 93). *NAT2* is not inducible to a significant extent *in vivo* (79, 89). Instead, *NAT2* genetic polymorphism is considered the most important underlying cause of the described variability (89, 92, 95, 96). It has been shown that frequencies of *NAT2* SNPs differ among ethnic populations, leading to substantial inter-ethnic variability in *N*-acetylation capacity (79, 88, 90, 92, 93, 97).

NAT2 participates in metabolism of caffeine by converting 17X into AFMU (48, 49). Since it is much safer than other *NAT2* probe drugs, e.g. sulfamethazine or isoniazid, caffeine test is considered the most appropriate for the assessment of *in vivo* *N*-acetylation status (92). Both AFMU/1X and AFMU/(AFMU+1X+1U) urinary ratios are proved to be reliable indicators of *NAT2* enzyme activity (62, 84, 92, 98).

1.2.4 XO

Xanthine oxidase (XO) is an important phase I enzyme, in humans predominantly expressed in the liver and intestine (99-101). It catalyzes essential constitutive reactions involving endogenous purines, pyrimidines and aldehydes, with the conversion of hypoxanthine to xanthine and further to uric acid as one of its primary roles (100, 102-107). In addition, XO is responsible for biotransformation of several xenobiotics, including clinically important drugs such as allopurinol, acyclovir, mercaptopurine, azathioprine, pyrazinamide, methotrexate, fluorouracil, doxorubicin, daunomycin, and mitomycin C, as well as caffeine (99-101, 103, 106-108).

The human *XO* gene is localized on chromosome 2 (2p22), it consists of 36 small exons spanning a region of over 60 kbp (100, 104). Variations of the gene have been described, but they rarely proved to be functional (91, 101).

There are marked inter-individual and inter-ethnic differences in XO activity, with approximately 20% of Caucasians, 11% of Japanese and 4% of Ethiopians displaying lower enzyme activity (62, 84, 101, 109, 110). In addition, XO can be up- or down-regulated under a variety of non-genetic factors (104). It has been observed that its level and activity increases during certain diseases, such as arthritis, asthma, viral hepatitis, and hypoxia-reperfusion injury (104-108, 111, 112), and the inducing effect has been attributed to cytokines, including tumor necrosis factor- α , interleukin-1 β , and interferon- γ (104, 105). XO activity can be induced by xenobiotics too, both drugs (dexamethasone, ethacrynic acid and iron) and hepatotoxic agents, such as halothane

alcohol, carbon tetrachloride and 2,3,7,8-tetrachlorodibenzo-p-dioxin (91, 101, 106, 107, 113). On the other hand, XO can be inhibited by allopurinol and its metabolite oxypurinol, and this effect serves as a foundation in the treatment of hyperuricemia and its complications (91, 106, 107). It is generally accepted that cigarette smoking does not affect XO activity (84, 108, 110), but numerous investigations of possible sex differences yielded contradictory results (62, 84, 99, 102, 108, 110).

XO participates in the metabolism of caffeine by converting 1X to 1U (47). Thus, caffeine as a probe and urinary (1U)/(1X+1U) ratio has been accepted as appropriate for estimation of *in vivo* XO enzyme activity (47, 91, 99, 101, 103).

2 OBJECTIVES

The general objective of the study was to investigate the influence of pharmacogenetic and environmental factors on the activity of drug metabolizing enzymes involved in caffeine disposition, namely CYP1A2, CYP2A6, NAT2 and XO, in three ethnically distinct populations: Serbs, Swedes and Koreans.

Specific objectives of the study were as follows:

1. To investigate the effect of regular heavy coffee consumption, *CYP1A2* genotype and ethnicity on CYP1A2 enzyme activity (**papers I, II**).
2. To investigate the effect of sex, age, cigarette smoking, OC use, *CYP2A6* genotype and ethnicity on CYP2A6 enzyme activity (**paper V**).
3. To investigate the effect of sex, cigarette smoking, OC use, *NAT2* genotype and ethnicity on NAT2 enzyme activity (**papers III, IV**).
4. To investigate the effect of sex, cigarette smoking, OC use and ethnicity on XO enzyme activity (**paper IV**).

3 MATERIALS AND METHODS

3.1 SUBJECTS

The study involved unrelated healthy volunteers of three distinct ethnic origins: Serbian, Swedish and Korean. Serbs (n=140) were 18 to 46 years old (median age: 27 years), and the group included 72 men, 38 smokers (smoking on average two or more cigarettes per day), 47 heavy coffee consumers (regularly drinking three or more cups of coffee per day), and no oral contraceptive (OC) users. Swedes (n=190) were 18 to 60 years old (median age: 29 years), and in the group there were 79 men, 39 smokers, 63 heavy coffee consumers and 44 OC users. Koreans (n=150) were 20 to 46 years old (median age: 25 years) and included 74 men, 28 smokers and only one OC user, while the data on regular coffee consumption were not available. None of the study subjects used any medications, were pregnant or breast-feeding.

As some of the data, including genotyping and phenotyping results, were missing at random (could not be obtained for some of the subjects), subjects with missing data were excluded from certain analyses, i.e. complete case analysis approach was introduced. In addition, some of the analyses required specific exclusion criteria to be met, e.g. in paper II the effect of heavy coffee consumption could not be tested in smokers. Therefore, the sample size differed: paper I included 100 Serbs and 149 Swedes, paper II were based on the data obtained from 126 Serbs and 114 Swedes, paper III involved 140 Serbs, 113 Swedes and 150 Koreans participated in paper IV, while 190 Swedes and 144 Koreans took part in paper V.

3.2 STUDY DESIGN

All study subjects were advised to abstain from any form of caffeine intake, including coffee, tea, chocolate and other caffeine-containing food or beverage consumption, for at least (114) 24 h prior to and throughout the study. After completing the wash-out period, subjects received single oral dose of 100 mg caffeine (Koffein Recip; Recip AB, Årsta, Sweden) and answered a detailed questionnaire about their smoking habit, regular coffee consumption and OC use (115).

Four hours after caffeine intake (68), a 20-ml venous blood sample was drawn into EDTA-containing vacutainer tubes (Sarstedt, Nümbrecht, Germany): 10ml was kept as a whole blood sample, and 10ml was centrifuged and plasma separated. In addition, 8-hours urine was collected, pH adjusted to 3.5 with 0.1 M HCl to ensure the stability of AFMU (85) and 20-ml aliquots were stored.

All samples were frozen at -80°C . Blood and plasma samples collected outside Stockholm (in Serbia and Korea) were packed on dry ice and sent to Karolinska University Hospital, Huddinge, Sweden, where genotyping and CYP1A2 phenotyping analyses were performed. Urine samples were sent to Extremadura University in Badajoz, Spain, for CYP2A6, NAT2 and XO phenotype analyses.

3.3 LABORATORY ANALYSES

3.3.1 Genotyping

Genomic DNA was extracted from the whole blood samples using QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany). DNA concentration and purity were measured using DU[®]530 Life Science UV/Visible Spectrophotometer (Beckman Coulter, Fullerton, CA).

Genotyping for ***CYP1A2* polymorphisms (paper II)** -3860G>A (rs2069514), -739T>G (rs2069526), -729C>T (rs12720461), -163C>A (rs762551), 2159G>A (rs2472304), 4795G>A (rs12904742) was carried out using the tag-array minisequencing method according to Lindros et al.(116). In brief, DNA fragments spanning *CYP1A2* polymorphic sites of interest were amplified by multiplex PCR reaction, using six PCR primer pairs on GeneAmp[®] PCR System 2700 (Applied Biosystems, Foster City, CA). After removing excess of PCR primers and dNTPs, products of multiplex PCR reaction were subjected to minisequencing reaction on PTC-225 Peltier Thermal Cycler (Bio-Rad, Hercules, CA, USA), with the extension mix that contained fluorophore-labelled ddNTPs and tagged minisequencing primers. Multiplex PCR and minisequencing primers were designed by OligoPerfect Designer (www.invitrogen.com) and Auto-Primer software (<http://www.autoprimer.com/>), respectively, and purchased from Integrated DNA Technologies (IDT, Coralville, IA, USA). Products of minisequencing reaction were then pipetted onto the microarray, spotted with oligonucleotides complementary to the “tag” sequence of the minisequencing primers. After completed hybridization, fluorescence signals from microarray were measured using ScanArray Express HT[®] microarray scanner (Perkin Elmer Life and Analytical Sciences, Inc., Waltham, MA) and QuantArray[®] 2001 software, version 3.0.0.0 (Packard BioScience Company, Meriden, CT). The QuantArray file was exported and analysed using the SNPSnapper analysis software, version 4.0 beta, (<http://www.bioinfo.helsinki.fi/SNPSnapper>). SNPs were detected based on the type of the fluorescence signal (Texas-Red–ddATP, Tamra–ddCTP, R110–ddGTP, Cy5–ddUTP) received from the specific position on the microarray.

In addition, *CYP1A2* polymorphism –2467delT (rs35694136) was determined by PCR-RFLP method described by Chida et al. (117). In short, the fragment of *CYP1A2* spanning the SNP was amplified in the PCR reaction on GeneAmp[®] PCR System 9700 (Perkin-Elmer Applied Biosystems, Foster City, CA) and then subjected to the restriction enzyme NdeI (New England Biolabs, Ipswich, MA). As enzyme cuts only wild type allele to fragments of 149 bp and 18 bp, SNP detection was conducted using electrophoresis on 2% agarose gel.

Genotyping for ***CYP2A6* polymorphisms (paper V)** gene deletion, gene conversion in the 3' region, 1436G>T (rs5031017), 1412T>C (rs5031016), 1454G>T (rs28399468) and gene duplication was carried out using the AS-PCR methods, as previously described in the literature. In brief, gene deletion was detected using nested AS-PCR reaction (118), with the first PCR reaction used to amplify the region common for both *CYP2A6* and *CYP2A7* genes, followed by a second amplification with primers specific for either wild type or *CYP2A6del* allele. Gene conversion in the 3' region and

1436G>T were also detected by nested AS-PCR reaction (119), where the first PCR reaction was common for both SNPs, and the allelic discrimination was performed separately with different primer pairs. Similar nested AS-PCR methods was used for separate genotyping of 1412T>C (rs5031016) and 1454G>T (rs28399468) (120). Genotyping for gene duplication was performed by one-step AS-PCR method, with either *CYP2A7*-specific or *CYP2A6*-specific forward primer in addition to *CYP2A7* reverse to distinguish between the wild-type *CYP2A7* and the duplicated *CYP2A6*, respectively (76). All PCR reactions were performed on GeneAmp PCR System 2700 (Applied Biosystems, Foster City, CA), and the products were detected by electrophoresis on 1.2% agarose gel.

CYP2A6 polymorphism -48T>G (rs28399433) was determined using newly designed nested AS-PCR method. First PCR reaction was performed with 5'-TGGCTGTGTCCCAAGCTAGGCA-3' as forward and 5'-CTTCATGAGGGAGTTGTACATC-3' as reversed primer, in the following conditions: initial denaturation at 95°C for 1 min; 35 cycles of denaturation at 95°C for 15 s, annealing at 56°C for 20 s, extension at 72°C for 90 s; final extension at 72°C for 7 min. In AS-PCR reaction, allele-specific forward primer 5'-CTTTTTCAGGCAGTAT-3' or 5'-CTTTTTCAGGCAGTAG-3' was used with the common 5'-CTTCATGAGGGAGTTGTACATC-3' reversed primer, and the reaction conditions were as follows: initial denaturation at 95°C for 1 min; 15 cycles of denaturation at 95°C for 15 s, annealing at 54°C for 20 s, and extension at 72°C for 45 s; and final extension at 72°C for 7 min. PCR reactions were performed on GeneAmp PCR System 2700 (Applied Biosystems, Foster City, CA). PCR products were detected by electrophoresis on 1.2% agarose gel.

Genotyping for ***NAT2* polymorphisms (papers III, IV)** 190C>T (rs1805158), 403C>G (rs12720065), 411T>A (rs4986997), 590G>A (rs1799930), 803A>G (rs1208), and 857G>A (rs1799931) were carried out using the tag-array minisequencing method according to Lindros et al.(116), as described above. *NAT2* polymorphisms 191G>A (rs1801279), 282C>T (rs1041983), 341T>C (rs1801280), and 481C>T (rs1799929) were detected using restriction fragment length polymorphism (RFLP) or allele-specific (AS) PCR reaction, as reported by Anitha and Banerjee (121). Briefly, after amplifying approximately 1.2 kb of *NAT2* gene region of interest, PCR products were separately digested by the restriction enzymes *MspI*, *FokI* and *KpnI* (New England Biolabs, Ipswich, MA) and the pattern of restrictions were examined to detect 191G>A, 282C>T and 481C>T, respectively. On the other hand, to distinguish between T and C at the position 341, two separate PCR reactions with either wild- or variant-specific forward primer and the common reverse primer were performed on GeneAmp PCR System 2700 (Applied Biosystems, Foster City, California). Both RFLP- and AS-PCR products were analyzed by gel electrophoresis on 1.2% agarose gel.

Furthermore, coding regions of the *NAT2* gene were amplified, purified and sequenced in both forward and reverse directions, using the ABI PRISM™ BigDye terminator cycle sequencing ready reaction kit version 3.1 (Applied Biosystems, Foster City, California) and ABI Prism 377 DNA sequencer. *NAT2* sequence chromatograms were analyzed using software FinchTV version.1.4.0 (<http://www.geospiza.com>) and aligned

with the NAT2 reference sequence (<http://www.ncbi.nlm.nih.gov>; GenBank reference: NM 000015.2) for SNPs identification.

In addition, Serbian subjects (paper III) were genotyped for three common *NAT1* polymorphisms coding for the NAT1 fast acetylators phenotype, namely 445G>A, 640T>A and 1088T>A. Genotyping for 445G>A and 640T>A was performed by real-time PCR and the Taqman genotyping assays using the ABI 7500 FAST (Applied Biosystems, Foster City, California) (122). Genotyping for 1088T>A was performed as described by Henning et al. (123), using two-step (nested) AS-PCR reaction: first amplification that used one pair of primers was followed by AS-PCR for allelic discrimination, i.e. two separate PCR reactions with different forward primers and the common reverse primer. AS-PCR products were analyzed by gel electrophoresis on 1.2% agarose gel.

Genotyping of *XO* was not performed, since this gene is not considered significantly polymorphic (91, 101).

3.3.2 Phenotyping

Phenotyping of CYP1A2, CYP2A6, NAT2 and *XO* was performed using caffeine (Koffein; ACO AB, Helsingborg, Sweden) as a probe drug and measuring concentration of parent compound and its metabolites in plasma or urine samples.

To estimate *in vivo* **CYP1A2 enzyme activity (papers I, II)**, molar concentrations of caffeine (1,3,7-trimethylxanthine or 137X) and its metabolites paraxanthine (1,7-dimethylxanthine or 17X) were determined in plasma samples according to Ghotbi et al. (27), using reversed-phase HPLC with UV detection. In short, caffeine and paraxanthine were extracted from 100 μ plasma samples with 300 μ l acetonitrile, after addition of 25 μ l of 50 μ M internal standard (β -hydroxyethyl-theophiline). The organic phase was evaporated to dryness at the room temperature under nitrogen. After resolving the residue in 50 μ l mobile phase, 15 μ l was injected into the column. All samples, standards and quality controls were measured in one run and in duplicate. The flow rate was 1.0 ml/min and the compounds were monitored at 273.0 nm. The retention time was 5.5 - 7.6 min and 11.5 - 16.7 min for paraxanthine and caffeine, respectively. Calibration curves were linear, with the coefficients of correlation higher than 99%. At 16.3 μ M for caffeine and 10.3 μ M for paraxanthine, within-day and between-day coefficients of variations were less than 10 and 5% respectively. The HPLC equipment for the caffeine assay included 402 Dilutor-Dispenser (Gilson Inc., Middleton, WI), 231 XL Sample Injector (Gilson Inc., Middleton, WI), Dionex P580 Pump P480 (Dionex, Sunnyvale, CA) and 1010 Model Lambda - UV/VIS-Detektor (Bischoff, Leonberg, Germany). For the separation of molecules we used C18 Luna column (100 \times 4.6 mm ID, 3 μ m), and the precolumn Security Guard Cartridges C18, 4 \times 3 mm, both purchased from Phenomenex Inc., Torrance, CA. Chromatographic data were registered and processed by ELDS Win Pro v 1.1 software (Chromatography Data System, Svartsjö, Sweden). *In vivo* CYP1A2 enzyme activity was estimated by the 17X/137X ratio (124).

To estimate *in vivo* **CYP2A6 enzyme activity (paper V)**, high-performance liquid chromatography (HPLC) was used to determine the molar concentrations of caffeine metabolites 17X (1,7-dimethylxanthine or paraxanthine) and 17U (1,7-dimethyluric acid) in collected urine samples, according to Carrillo et al. (125). In brief, 17X and 17U were extracted simultaneously with 4 ml chloroform/isopropanol, after the addition of 6 µg/50 µl internal standard (N-acetyl-p-aminophenol) and 120 mg ammonium sulfate. The organic phase was evaporated to dryness at 45°C under nitrogen, the residue reconstituted in 200 µl mobile phase, and 50 µl injected onto a Ultrasphere-IP (5 µm particle size, 250 × 4.6 mm ID) reversed-phase column (Beckman Instruments, Madrid, Spain), eluted isocratically with acetic acid/acetonitrile/tetrahydrofuran/water (1:40:2:957 v/v). The flow rate was 1.0 ml/minute and the detection wavelength was 280 nm. Standard curves were with the coefficients of correlation higher than 99%. The limits of detection for the metabolites were within the range of 0.1 to 0.3 µmol. Within-day and intra-assay coefficient of variation (CV) was less than 10% at all concentration levels and for all metabolites, and the accuracy was between 96% and 105%. System Gold Microbore HPLC with 32 Karat Software (Beckman Instruments, Madrid, Spain) was used to process the HPLC data. *In vivo* CYP2A6 enzyme activity was estimated by the 17U/17X ratio (81, 87).

In vivo **NAT2 and XO enzyme activities (papers III, IV)** were assessed by the caffeine urinary test, according to Carrillo et al. (125). Molar concentrations of caffeine metabolites AFMU (5-acetyl-amino-6-formyl-amino-3-methyluracil), 1X (1-methyl xanthine) and 1U (1-methyluric acid) were determined by HPLC method, as described above. *In vivo* NAT2 and XO enzyme activities were estimated by the AFMU/(AFMU+1X+1U) and 1U/(1U+1X) ratios, respectively (84, 110, 126).

3.4 STATISTICAL ANALYSES

All statistical analyses were performed with Statistica, version 7.1 (StatSoft Inc, Tulsa, OK, USA). For all statistical procedures, $P < 0.05$ was considered as significant.

The 17X/137X, 1U/(1U+1X), AFMU/(AFMU+1X+1U) and 17U/17X ratios were log-transformed before statistical analyses, and their normality of distribution was assessed by Kolmogorov-Smirnov or Shapiro-Wilk test (**papers I-V**). Student's t-test, Mann-Whitney test or one-way analysis of variance (ANOVA) followed by the post-hoc analyses were used to determine the influence of different factors on CYP1A2 enzyme activity (**papers I, II**). Haplotype analysis was carried out using the population genetic software program Arlequin, version 3.11 (<http://cmpg.unibe.ch/software/arlequin3>), and chi-square test was used to compare obtained with expected allele frequencies, i.e. to test the consistency with the Hardy-Weinberg equilibrium (**papers II-V**). Kruskal-Wallis analysis, ANOVA followed by the post-hoc analyses or multiple linear regression were used to assess the effect of possible influencing factors on NAT2 and XO activity (**papers III, IV**). Effect on CYP2A6 enzyme activity was tested by multiple regression analysis (**paper V**).

3.5 ETHICAL CONSIDERATIONS

All subjects participated voluntarily in the studies after signing written informed consent. The study was conducted in accordance with the Declaration of Helsinki and its subsequent revisions, and approved by the ethics committees at the Karolinska Institutet, Stockholm, Sweden, No.2009/219-32 (**papers I-V**), the Medical Faculty, University of Kragujevac, Serbia, No.01-1995, No.01-4502, No.01-6427/6 (**papers I-III**), and at the Inha University Hospital, Korea (**papers IV, V**).

4 RESULTS

4.1 CYP1A2

Having analyzed only non-OC users, significantly higher CYP1A2 enzyme activity in heavy coffee consumers compared to non-heavy coffee consumers was observed in Swedish (n=149, $P<0.0001$; 95% CI of the mean difference 0.06, 0.16) and Serbian (n=100, $P=0.0002$; 95% CI of the mean difference 0.08, 0.21) subjects. In both populations, the observed difference remained significant when additionally controlling for smoking, i.e. when analysis was performed among Swedish (n=114, $P=0.02$; 95% CI of the mean difference 0.01, 0.12) and Serbian (n=72, $P=0.003$; 95% CI of the mean difference 0.04, 0.18) non-smokers. In smokers, however, only Swedes displayed higher CYP1A2 activity if heavy coffee consumers (n=35, $P<0.0001$; 95% CI of the mean difference 0.13, 0.33), while no significant difference was observed among Serbian smokers (n=28, $P=0.77$) (**paper I**).

Effect of *CYP1A2* genotype on enzyme activity was analyzed among non-OC users and non-smokers, and $-163C>A$ polymorphism was detected as the only predictor. Significantly higher CYP1A2 activity was observed in carriers compared to non-carriers of $-163C>A$ polymorphism in both Swedish (n=42, $P=0.016$) and Serbian (n=17, $P=0.022$) heavy coffee consumers. The highest enzyme activity among heavy coffee consumers was detected in the $-163A/A$ genotype group in both populations, observed as significantly higher compared to homozygous carriers of variant type allele among Swedes ($P=0.036$; 95% CI of the mean difference 0.01, 0.23) and Serbs ($P=0.001$; 95% CI of the mean difference 0.09, 0.36). However, among non-heavy coffee consumers no significant effect of $-163C>A$ polymorphism on CYP1A2 enzyme activity was observed in either Swedes (n=72, $P\geq 0.31$) or Serbs (n=47, $P\geq 0.15$). In addition, the inducing effect of heavy coffee consumption on CYP1A2 activity was observed only in carriers of $-163A/A$ genotype in both Swedes (n=46, $P<0.0001$; 95% CI of the mean difference 0.08, 0.22) and Serbs (n=22, $P=0.005$; 95% CI of the mean difference 0.06, 0.28) (**paper II**).

When controlling for the effect of cigarette smoking, heavy coffee consumption and OC use, significantly higher CYP1A2 enzyme activity ($P=0.0003$; 95% CI of the mean difference -0.14, -0.04) was observed in Swedes (n=72) compared to Serbs (n=54) (**paper I**).

4.2 CYP2A6

Except for the $1436G>T$ polymorphism that was absent in both populations, the distribution of *CYP2A6* variant alleles and genotypes was significantly different between Swedes and Koreans ($P\leq 0.002$). The distribution of genotype groups, appointed according to the presence of functional (**1A*, **1x2*, or **1B1*) or less functional/non-functional *CYP2A6* alleles (**4*, **7*, **8*, **9* and **10*), also significantly differed between the populations ($P<0.0001$), revealing rapid (95% CI of the difference in proportions 0.44, 0.62) and slow (95% CI of the difference in proportions -0.32, -0.18) genotype groups as the most prevalent among Swedes and Koreans, respectively.

CYP2A6 genotype significantly affected enzyme activity in both populations ($P=0.004$), while no effect of sex ($P=0.14$), age ($P=0.32$), cigarette smoking ($P=0.39$) or OC use ($P=0.59$) was observed (**paper V**).

The 17U/17X ratios in Swedes ($n=190$) ranged from 0.00 to 2.81 (median: 0.50), while in Koreans ($n=144$) were between 0.00 and 1.96, with the median value of 0.22. The probit transformation indicated common antimode at 0.01, with 3.16% of Swedes and 18.75% of Koreans having phenotype of slow metabolizer ($P<0.0001$; 95% CI of the difference in proportions -0.22, -0.09). *CYP2A6* enzyme activity was significantly higher in Swedes compared to Koreans ($P=0.0001$; 95% CI of the median difference 0.23, 0.46). The observed differences between the two populations remained significant when controlling for the genotype effect, i.e. within rapid ($P=0.0007$; 95% CI of the median difference 0.08, 0.40) and intermediate ($P=0.04$) genotype groups (**paper V**).

4.3 NAT2

The AFMU/(AFMU+1X+1U) ratios in Serbs ranged from 0.05 to 0.64 (median: 0.33), with clear antimodes at 0.09 and 0.25 that appointed 9% ($n=9$), 36% ($n=36$) and 55% ($n=55$) of Serbian subjects for slow, intermediate and rapid acetylators, respectively (**paper III**). The AFMU/(AFMU+1X+1U) ratios in Swedes and in Koreans were within the range from 0.00 to 0.53 (median: 0.02) and from 0.00 to 0.44 (median: 0.06), respectively. The antimode at 0.16 observed in Koreans denoted 25.9% of Korean subjects as rapid metabolizers, while in only 6.2% of Swedes the AFMU/(AFMU+1X+1U) ratios were above the same value ($P<0.0001$; 95% CI of the difference in proportions -0.28, -0.11) (**paper IV**).

Comparison between Swedes and Koreans revealed latter to have significantly higher NAT2 activity, and the difference remained significant when controlling for the influence of cigarette smoking, sex, or OC use ($P<0.0001$), as well as *NAT2* genotype ($P=0.016$). Stratified by genotype, Koreans display higher enzyme activity compared to Swedes among carriers of at least one wild type *NAT2*4* allele ($P=0.004$), while similar tendency of higher enzyme activity in Koreans than in Swedes was observed among slow acetylators ($P=0.31$) (**paper IV**).

With the frequency of 43%, the most common NAT2 haplotype in Serbs was *NAT2*5*, followed by *NAT2*6* that was present in 28% of Serbian subjects (**paper III**). Similar distribution was observed in Swedes, with 47% and 28% of subjects having *NAT2*5* and *NAT2*6* haplotype, respectively (**paper IV**). On the other hand, 65% of Koreans were carriers of wild type *NAT2*4*, *NAT2*6* had a frequency of 23%, while *NAT2*5* was extremely rare (0.2%) (**paper IV**).

When stratified based on the presence or absence of functional *NAT2*4*, *NAT2*12* or *NAT2*13* allele, Swedes and Koreans significantly differed in terms of distribution of genotype groups ($P<0.0001$). In Swedes, carriers of two, one and no functional alleles occurred with the frequencies of 8.85%, 29.20%, and 61.95%, respectively, whereas in Koreans the respective percentages were 40.67%, 48.67%, and 10.67% (**paper IV**). In Serbs, however, both alleles were functional in 4.9% of subjects, genotypes containing

only one functional allele had a frequency of 45.5%, while no functional alleles had 49.6% of the population (**paper III**).

Significant NAT2 genotype-phenotype association was detected in all three populations: in Serbs ($P < 0.0001$) (**paper III**), Swedes ($P = 0.03$) and Koreans ($P = 0.008$) (**paper IV**). Due to unexpectedly high frequency of rapid acetylators observed in Serbs, genotype-phenotype correlation was investigated in each of the Serbian subjects separately. It was observed that, of all slow/intermediate acetylators (AFMU/(AFMU+1X+1U) ratio below 0.25) who had their genotype determined ($n = 44$), in 93.2% observed phenotype was in agreement with the genotype, i.e. subjects were homozygous for the defective variant alleles. However, only 84.9% concordance with the genotype was observed within the rapid acetylator group (AFMU/(AFMU+1X+1U) ratio above 0.25, $n = 53$), that is, there were 8 subjects carrying both defective alleles, yet displaying high enzyme activity. Described NAT2 genotype-phenotype discordance could not be explained by NAT1 gene polymorphism, as there was no significant differences in NAT1 alleles and genotypes frequency distribution between NAT2 phenotype ($P = 0.36$) or genotype groups ($P = 0.07$) (**paper III**).

No significant influence of smoking on NAT2 activity was observed in either Serbs ($P = 0.57$) (**paper III**), Swedes ($P = 0.14$) or Koreans ($P = 0.05$) (**paper IV**). Similarly, there was no significant difference between men and women within Serbian ($P = 0.94$) (**paper III**), Swedish ($P = 0.74$) and Korean ($P = 0.39$) population (**paper IV**). On the other hand, significant correlation of OC use and NAT2 activity was observed in Swedish women ($P = 0.007$; 95% CI of the median difference -0.53, -0.21), users ($n = 33$, median: 0.04) having significantly higher enzyme activity compared to non-users ($n = 38$, median: 0.02) (**paper IV**). This effect could not be evaluated in other two populations, as none and only one woman used oral contraceptives in Serbs and Koreans, respectively (**paper III, IV**).

4.4 XO

The 1U/(1U+1X) ratios in Swedes and Koreans ranged from 0.01 to 0.98 in former and from 0.00 to 0.98 in latter, with the median values of 0.46 and 0.48, respectively. The common antimode at 0.08 identified 6.4% of Swedes and 9.5% of Koreans as slow metabolizers. In terms of XO activity, no significant difference between the two populations was detected ($P = 0.40$) (**paper IV**).

XO activity was significantly influenced by sex in Swedes ($P = 0.003$; 95% CI of the median difference 0.06, 0.32), but not in Koreans ($P = 0.43$). In Swedes, higher 1U/(1U+1X) ratio was observed in women ($n = 70$, median: 0.53) compared to men ($n = 39$, median: 0.34), and the effect remained significant after the OC users were excluded from the comparison ($P = 0.01$). OC use ($P = 0.09$) and cigarette smoking ($P = 0.15$) did not affect XO activity in either of the populations (**paper IV**).

5 DISCUSSION

5.1 CYP1A2

In the present study, the main findings related to CYP1A2 activity are enzyme induction by habitual heavy coffee consumption in carriers of $-163C>A$ *CYP1A2* polymorphism, and higher CYP1A2 enzyme activity in Swedish compared to Serbian population (**paper I, II**).

Effect of heavy coffee consumption has been investigated in Serbian and Swedish healthy volunteers, none of which was using any medications, including oral contraceptives. Possible competitive inhibition was avoided by abstaining from intake of any caffeine-containing food, beverage and medication for at least 24 h before and during the study (114, 124). The results demonstrated that daily consumption of at least three cups of coffee increased CYP1A2 enzyme activity in all Swedes and Serbs. Since it is known that cigarette smoking induces CYP1A2 enzyme activity (52), effect of heavy coffee consumption among Swedes and Serbs was additionally analyzed when controlling for this confounding factor. Among non-smokers in both populations, heavy coffee consumers displayed higher enzyme activity compared to non-heavy coffee consumers. Similar results were obtained among Swedish smokers, but we were not able to show the same effect in Serbian smokers due to the low number of subjects in this group (**paper I**).

The general mechanism of CYP1A2 induction is well known and includes ligand-dependent activation of aryl hydrocarbon receptor (AHR) - aryl hydrocarbon receptor nuclear translocator (ARNT) pathway (48, 127). Upon ligand binding, AHR translocates from cytoplasm into the nucleus, and with ARNT protein, already present in the nucleus, forms a heterodimer. This complex then recognize and binds to one of the several xenobiotic response elements (XRE), localized within the promoter region of *CYP1A2* gene, and in turn induce transcription activation (52, 128, 129). The ligands that activate AHR could be certain environmental chemicals, of which the most common are polycyclic aromatic hydrocarbons (PAHs) (127). PAHs are produced by incomplete combustion processes of organic material at high temperatures (130, 131), and could be found in cigarette smoke and grilled meat – both known inducers of CYP1A2 activity (48, 52, 132).

Coffee is a complex chemical mixture of over 1000 different chemicals, with caffeine, its best-known component, participating with only 1 % (34). According to previous investigations, caffeine has a very low affinity for the AHR (133). Furthermore, CYP1A2 induction was observed to be more dependent on a regular coffee consumption than on an overall caffeine intake (63), suggesting that effect of some other coffee constituent might be more important than the effect of caffeine itself. In addition, *in vitro* studies reported that coffee consumption up-regulate glucuronidation by AHR signaling, but that this process takes place independently of caffeine (134). At the same time, all types of coffee beans have to be roasted before preparation and the temperature during roasting reaches up to 260°C (34, 135). Thus, the concentration of PAHs, which are already present in green coffee beans, increases during the roasting

process (135), and reach up to 1.8 µg of PAHs per liter of coffee brew samples (136). According to our results, regular heavy coffee consumption induces CYP1A2 activity. Based on the data from the literature, we presume polycyclic aromatic hydrocarbons to be at least partly responsible for this effect.

CYP1A2 is known to be polymorphic, with several polymorphisms having an impact on drug metabolism (48, 52). Of those, substitution C>A at position -163 is one of the most common in Caucasians, with frequencies that range from 33.8% in British (137) to 71.4% in Swedish population (27). Its importance for CYP1A2 enzyme activity was first observed by Sachse et al. (54) as higher enzyme inducibility by cigarette smoking in the presence of -163A/A genotype. Several subsequent studies (27, 56, 138, 139), but not all (57, 140, 141), confirmed this observation by reporting higher CYP1A2 enzyme activity in the presence of CYP1A2 inducers, such as cigarette smoking or omeprazol.

To investigate the possible effect of *CYP1A2* genetic polymorphism on enzyme induction by heavy coffee consumption, we compared enzyme activity among Serbian and Swedish heavy and non-heavy coffee consumers, controlling for the influence of cigarette smoking and OC use. In heavy coffee consumers, the highest CYP1A2 enzyme activity was detected in carriers of -163A/A genotype. The inducing effect of heavy coffee consumption was observed only in subjects homozygous for the variant -163A allele. In non-heavy coffee consumers, influence of -163C>A was not observed (**paper II**).

To the best of our knowledge, this is the first study to report increased CYP1A2 inducibility by heavy coffee consumption in carriers of -163A/A genotype. Significant genotype-phenotype association was analyzed and confirmed independently in two different populations, regardless of possible linkage disequilibrium with other *CYP1A2* polymorphisms. It is interesting to note that among all heavy coffee consumers inducing effect was observed only in carriers of -163A/A genotype, while among all carriers of -163A/A genotype higher enzyme activity was observed only in heavy coffee consumers. Based on these observations, both -163A/A genotype and an inducer, such as heavy coffee consumption, seem to be necessary for the CYP1A2 induction. Our results suggest that regular heavy coffee consumption might be a possible confounding factor for the discrepant findings in studies investigating the association of -163C>A *CYP1A2* polymorphism with CYP1A2 enzyme induction.

Previous studies, comparing black with white populations (62, 65), or Koreans with Swedes (27), reported the influence of ethnicity on CYP1A2 activity. Within Caucasian population, significantly higher CYP1A2 activity has been observed among residents of Germany compared to subjects living in Bulgaria and Slovakia (63). In the present study, two populations, both of Caucasian origin but representing different ethnic groups, were compared in terms of CYP1A2 enzyme activity. The comparison revealed significantly higher enzyme activity in Swedes compared to Serbs (**paper I**).

The effects of ethnicity on drug metabolism can be determined by both genetic and environmental factors, including diet, lifestyle and concomitant use of medications (9). In the present study, inter-ethnic variation in CYP1A2 enzyme activity was investigated

by comparing healthy unrelated Swedish and Serbian volunteers, who were not using any medications, including OC. The frequency of -163C>A *CYP1A2* polymorphism was similar between the population, and the influence of cigarette smoking and heavy coffee consumption was ruled out by excluding smokers and heavy coffee consumers from the comparison. The reason for the observed difference remains to be additionally investigated, with other *CYP1A2* genetic variants, epigenetic regulation or unreported intake of herbal preparations as possible explanations (25, 52, 127, 142, 143).

5.2 CYP2A6

Regarding *CYP2A6*, the most important observation of this study is the difference between Swedish and Korean population in terms of both *CYP2A6* genotype and enzyme activity. Unlike sex, age, cigarette smoking and OC use, *CYP2A6* genotype significantly affected *CYP2A6* enzyme activity (**paper V**).

Based on the earlier investigations, *CYP2A6* genetic variation has been suggested to be the leading cause for the variability in enzyme activity (69, 74, 75, 86). In the present study, Swedish and Korean subjects were genotyped for functional variant alleles previously found in Caucasians and/or Asians, and the results corresponded well with the earlier reports (75-77, 144-149). In Swedes, the most frequently found were rapid genotypes, consisting of both functional alleles, whereas in Koreans the most numerous were the carriers of slow genotype with both alleles nonfunctional. As expected (73, 150), the effect of genotype on *CYP2A6* activity was confirmed in both populations (**paper V**).

Inter-ethnic differences in *CYP2A6* activity have already been studied, and significantly lower enzyme activity was observed in African Americans and Asians compared to Caucasians in general (151, 152). Additionally, when comparing with black and white populations and between each other, Japanese displayed the lowest and Koreans the highest *CYP2A6* activity (146, 148). In the present study we detected higher *CYP2A6* activity in Swedes compared to Koreans (**paper V**). Since rapid *CYP2A6* genotypes were more frequent in Swedes and slow in Koreans, the observed difference in enzyme activity between the populations could be explained by genotype effect. Nevertheless, after stratification according to the genotype Swedes still displayed higher enzyme activity, indicating that, although it contributes to, the investigated *CYP2A6* genetic polymorphisms cannot fully explain inter-ethnic variability in *CYP2A6* enzyme activity. Possible reasons for the observed difference could include other *CYP2A6* genetic variants, epigenetics or diet (146, 148, 153).

Considerable controversy about possible effect of sex on *CYP2A6* activity dwells in the available literature. Some of the previous studies, investigating Caucasians (75, 82, 152, 154), Africans (83, 148), and Asians (155), reported higher enzyme activity in women compare to men. Since increased enzyme activity have been observed in OC users too (72, 82), female sex hormones were suggested as responsible for the inducing effect of on *CYP2A6* activity (82). However, other studies failed to find any significant sex differences in enzyme activity in either Caucasians (81, 84, 148, 156) or Asians (157). Similarly, in the present study we did not observe any effect of either sex or OC use on *CYP2A6* activity in Swedes or in Koreans (**paper V**). It is known that sex-

related differences in pharmacokinetics could be important determinants of inter-individual variation in drug response (3, 4, 8-10), with body mass index and hormonal status as the most likely underlying cause (158). Yet, many of the studies on sex-based inter-individual differences in drug metabolizing enzyme activity have been performed in small number of subjects, thus producing inconclusive results (158). Regarding CYP2A6, the influence of sex and OC use on enzyme activity remains controversial, thus future studies, taking account both sample size and possible confounders, such as body weight or hormonal replacement therapy, will be needed to resolve this issue.

Although the hypothesis that activity of CYP2A6 activity could change with age was not widely investigated, some of the studies did describe significantly higher enzyme activity in older individuals (72, 154, 156). Consistently with the opposite reports, in the present study, involving subjects from 18 to 60 years old, no association of CYP2A6 activity with age neither in Swedes nor in Koreans was observed (**paper V**). Our finding is in accordance with the experimental data demonstrating that the content and activities of various CYP450 enzymes practically do not decline with age in healthy subjects (159-162). Most probably, seeming age effect on CYP2A6 activity observed in several previous studies might be the due to unrecognized chronic liver disease or unreported intake of CYP2A6 inducers or inhibitors (159-161).

The effect of cigarette smoking on CYP2A6 activity, assuming competitive enzyme inhibition by nicotine, was much more intensively studied (70, 81). Some of the studies identified expected decrease in enzyme activity in smokers (75, 81, 83, 145), while others did not observe any influence of cigarette smoking habit on CYP2A6 (72, 84, 156). The results of the present study are consistent with the latter reports, as sought effect of smoking was not detected in either Swedes or Koreans (**paper V**). It is well known that nicotine is almost exclusively metabolized by the CYP2A6 enzyme (86), thus the competitive inhibition of caffeine metabolism by cigarette smoking could be expected. Yet, since the conversion of 17X to 17U, which depends on CYP2A6, is not saturable in physiological conditions (163, 164), the nicotine effect, if exists, might not be very significant, necessitating larger sample size for detection. In addition, unreported intake of herbal preparations or nicotine replacement therapy should be considered as confounders.

5.3 NAT2

The most important findings of this study related to NAT2 include higher enzyme activity in Koreans compared to Swedes (**paper IV**), and unprecedentedly high prevalence of rapid acetylators in Serbian population (**paper III**). All three populations differed in terms of *NAT2* genotype distribution, but in all significant genotype-phenotype association was detected (**paper III, IV**). Yet, in Serbs partial discordance between rapid acetylator phenotype and *NAT2* genetic background was observed, which could not be explained by *NAT1* gene polymorphism either (**paper III**). Sex and cigarette smoking did not affect NAT2 activity in either of the populations (**paper III, IV**), while in Swedish women OC users had higher enzyme activity (**paper IV**).

NAT2 gene is known to be highly polymorphic (92, 95). In the present study, the most important nonsynonymous gene polymorphisms have been determined, and subjects

were stratified according to the genotype to either fast (carriers of at least one *NAT2* functional allele) or slow genotype group (165, 166). Additionally, fast genotype group was further divided into intermediate and rapid group, consisting of carriers of one and two functional alleles, respectively. The allele frequencies observed in Serbs, Swedes and Koreans were as expected for populations belonging to Caucasians and Asians, respectively. (166-170). Comparison among the populations revealed significant difference in the distribution of the *NAT2* genotypes. Namely, slow genotype was the most prevalent in Swedes and fast genotype in Koreans, while in Serbs both slow and fast genotypes were equally distributed (**paper III, IV**).

Significant correlation of *NAT2* genotype with *N*-acetylation capacity has already been reported by a number of studies, designating genetics as the most important determinant of inter-individual variation in NAT2 activity (89, 95, 98, 167). As expected, our study confirmed significantly high NAT2 genotype-phenotype correlation in all three investigated populations (**paper III, IV**). Nevertheless, certain discordance was observed in Serbian population, as the genotype did not correspond to observed acetylation status in all subjects. Namely, there were subjects having both functional alleles and displaying intermediate phenotype, as well as subjects carrying both defective alleles, yet displaying rapid phenotype (**paper III**). Although unusual, similar NAT2 genotype-phenotype discordance has already been reported in up to 10% of the population (89, 95, 96, 167). Other variations of *NAT2* gene were suggested as a plausible explanation for intermediate acetylators with rapid genotype finding (167), but sequencing of the *NAT2* coding region did not reveal any additional nonsynonymous polymorphism. Thus, either unknown variation within promoter region (97) or factors other than genetic variations, such as epigenetic influences (98) diet (79), or unreported traditional medications (171), might be responsible for the observed deviation within intermediate acetylator group. On the other hand, the presence of less functional allele renders NAT2 genotype slow regardless of other polymorphisms, thus additional *NAT2* genotyping could not explain discordance observed in rapid acetylator group. However, as NAT1 participates in caffeine metabolism by contributing to AFMU formation (166), *NAT1* genotyping was considered to be of importance: over-representation of *NAT1* fast alleles might have increased formation of AFMU and consequently AFMU/(AFMU+1X+1U) ratio, thus causing misclassification of NAT2 acetylators phenotype as rapid. To test the hypothesis, subjects were additionally genotyped for SNPs in the *NAT1* gene responsible for the fast NAT1 acetylation activity (95, 172-174). Nevertheless, fast *NAT1* alleles were similarly distributed among both NAT2 genotype-phenotype concordant and discordant subjects, and did not affect AFMU/(AFMU+1X+1U) ratio. Therefore, *NAT1* genetic polymorphism was excluded as an underlying cause for the observed NAT2 genotype-phenotype discordance within rapid acetylator group, and unreported environmental factors were suggested instead.

N-acetylation activity within populations usually follows bimodal or trimodal pattern, discriminating slow and intermediate from the rapid acetylator phenotype (62, 84, 166, 167, 175). In our study, Swedes displayed unimodal and Koreans bimodal NAT2 activity distribution, with lower *N*-acetylation capacity in Swedes compared with Koreans (**paper IV**). The observed difference was in accordance with the population-specific *NAT2* genotype distribution patterns, as the frequency of defective variant

alleles coding for the slow acetylator phenotype was higher in Swedes compared with Koreans. Inter-ethnic variations in NAT2 enzyme activity have already been observed (62, 79, 89, 90), including report of higher *N*-acetylation capacity in Caucasians compared to Asians (176), but the genotype effect was rarely considered. When we compared NAT2 activity between Swedes and Koreans while controlling for the *NAT2* polymorphism, the difference remained significant among carriers of fast genotype, while a similar tendency was observed between slow genotype groups (**paper IV**).

On the other hand, Serbs display trimodal distribution of NAT2 enzyme activity, with lower and upper antimode values at 0.09 and 0.25, respectively (**paper III**). Previous studies, using the same metabolic ratio as an index of NAT2 activity, set the lower limit for the rapid acetylators' phenotype between 0.2 and 0.3, regardless of the distribution pattern (62, 175, 177). This common cut-off point allowed us to compare our results with the previous reports for Caucasians, where the frequency of rapid acetylators, exceeding the similar cut-off point, was 44.9% or less (62, 84, 166), and slow acetylators phenotype was predominant. In contrast, our study revealed slow acetylator as the least common phenotype in Serbs, while 55% of subjects were designated as rapid acetylators, having AFMU/(AFMU+1X+1U) urinary ratio above upper antimode value of 0.25 (**paper III**). This unprecedented high prevalence of rapid acetylators in a white population could not be explained by either *NAT2* or *NAT1* genotypes, as both were found at frequencies consistent with the previous reports (122, 166-168, 178, 179). Our results of both comparison between Swedes and Koreans and phenotyping of Serbian population indicate that, in addition to *NAT2* genotype, ethnicity should be considered an important factor in treating patients with NAT2 metabolized drugs (169, 180). Inter-ethnic difference in *N*-acetylation capacity might be due to epigenetics, diet, or traditional medications (79, 98, 169, 175).

In agreement with the earlier reports (62, 79, 98, 181), sex or cigarette smoking did not affect NAT2 acetylation capacity in Serbs, Swedes or Koreans (**paper III, IV**). On the other hand, association between OC use and higher NAT2 activity was observed in Swedish women. Since only one Korean and none of the Serbian women used oral contraceptives, the finding could not be confirmed. It is known from previous animal studies that certain hormones can induce NAT2 via hormone-responsive elements (89). Yet, previous human study on OC use and NAT2 activity failed to find any significant association (181). Thus, to investigate the effect of steroid hormones on acetylation capacity in humans, as well as to explain the underlying mechanism of induction, additional studies will be necessary.

5.4 XO

The main findings of the present study related to XO comprise the lack of inter-ethnic difference between Swedes and Koreans and higher enzyme activity in Swedish women compared to men. Cigarette smoking and OC use did not affect XO activity in either of the populations (**paper IV**).

As a multifunctional enzyme involved in metabolism of both endogenous and exogenous substrates (104), XO has been widely investigated (62, 84, 108-110, 175, 181). Yet, although lower XO activity has been observed in black compared to

Caucasians (62), inter-ethnic differences were mainly reflected in the enzyme activity distribution pattern. Namely, in Caucasian populations XO activity were usually unimodally distributed (81, 84, 181), while others displayed bimodal distribution, with poor metabolizers ranging from 4% in Spaniards and Ethiopians (109, 110) up to 11% in Japanese (175). In the present study, in accordance with earlier studies comparing Caucasians and Chinese (64), comparison between Swedes and Koreans revealed the lack of interethnic variability in XO activity. Nevertheless, both Swedes and Koreans displayed bimodal distribution of XO activity (**paper IV**). In Koreans as an Asian population poor metabolizer phenotype was expected to be present (175), and its frequency corresponded well with the previously reported data. On the other hand, additional investigations, taking into account both XO genetic polymorphism (101) and environmental factors, will be needed to explain the slow metabolizer phenotype in the Swedish population.

Most of the previous studies did not observe any correlation between sex and XO enzyme activity (64, 108, 110, 175, 181). Nevertheless, Relling et al. (62) and Guerciolini et al. (102) reported higher and lower enzyme activity in women, respectively. In addition, Brown et al (182) described a positive association between female hormone levels and OC use with XO activity in human breast milk. In the present study, women displayed higher XO activity in Swedes but not in Koreans, while the influence of OC use was not observed (**paper IV**). Our results suggest sex as a factor to be considered for dose adjustments in Swedish patients treated with drugs metabolized by XO. On the other hand, it is generally accepted that cigarette smoking does not affect XO activity (108, 110, 175, 181). As expected, cigarette smoking did not affect XO activity in either Swedes or Koreans (**paper IV**).

6 CONCLUSIONS

- Habitual heavy coffee consumption induces CYP1A2 enzyme activity in carriers of *CYP1A2* –163A/A genotype.
- Swedes display significantly higher CYP1A2 activity compared to Serbs, and the observed difference is not due to *CYP1A2* genetic polymorphism, cigarette smoking, oral contraceptive use or heavy coffee consumption.
- *CYP2A6* genotype, but not sex, age, cigarette smoking and OC use, significantly affect CYP2A6 enzyme activity.
- Swedes display significantly higher CYP2A6 activity compared to Koreans, and the observed difference is mainly, but not entirely due to lower frequency of defective variant alleles in former compared to latter.
- *NAT2* genotype, but not sex and cigarette smoking, significantly affect NAT2 enzyme activity. In Swedish women, oral contraceptive use is associated with higher NAT2 enzyme activity.
- Koreans display significantly higher NAT2 enzyme activity compared to Swedes and the observed difference is mainly, but not entirely due to lower frequency of defective variants alleles in former compared to latter.
- Serbs differ from other Caucasians in terms of *N*-acetylation capacity, due to unprecedented high prevalence of rapid acetylator phenotype in the population. Partial NAT2 genotype-phenotype discordance observed in Serbian rapid acetylators could not be explained by *NAT1* gene polymorphism.
- Cigarette smoking and OC use do not affect XO enzyme activity. In Swedes, female sex is associated with higher XO enzyme activity.
- There is no inter-ethnic difference between Swedes and Koreans in terms of XO enzyme activity.

7 ACKNOWLEDGEMENTS

Many people in different ways contributed to this thesis, and I am truly grateful to all of them. Yet, my deepest appreciation undoubtedly belongs to my main supervisor, *Eleni Aklillu*, for accepting me as her student, always believing in me, encouraging me, supporting me and guiding me on my journey through pharmacogenetics. I am also most grateful to both of my co-supervisors: *Leif Bertilsson*, for generously sharing his great knowledge, experience and enthusiasm with me, and *Juan Antonio Carrillo*, for exciting and fruitful collaborative work.

I would also like to express my sincere gratitude to: *Stefan Lundgren*, for introducing me to the world of pharmacogenetics; *Anders Rane*, *Folke Sjökvist* and *Georgios Panagiotidis*, for giving me the opportunity to join KI; *Lilleba Bohman*, *Jolanta Widen*, *Birgitta Ask*, *Lena Ekström*, *Margit Ekström*, *Yvonne Sjöling* and *Margarita Mahindi*, for their kindness and invaluable help in the lab and with the administration; *Takashi Fukasawa*, *Ksenia Goryachkina*, *Mandana Shirazi*, *Parvaneh Afsharian* and *Aleksandra Trifunovic*, for their friendship and support, *Sarah Nanzigu*, *Roza Ghotbi*, *Lili Milani*, *Guillermo Gervasini*, *Hyung-Keun Roh*, *Sara Karlsson*, *Nobuhisa Ueda*, *Akira Suda*, *Slobodan Jankovic* and *Marieke PJ van den Broek*, for successful collaboration; *Rudolf Poredos*, for unceasing inspiration and support; as well as all the Serbian, Swedish and Korean volunteers, for their participation in the study.

Last, but not least: I would like to thank *my Dejan* and *my parents*, for loving me for who I am, always being by my side and supporting me selflessly.

8 REFERENCES

1. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. *Clin Pharmacol Ther.* 1983; 33(5): 591-602.
2. Wood AJ. Ethnic differences in drug disposition and response. *Ther Drug Monit.* 1998; 20(5): 525-6.
3. Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. *Curr Drug Targets.* 2006; 7(12): 1641-8.
4. Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. *J Clin Pharmacol.* 2003; 43(9): 943-67.
5. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. *Pharmacol Rev.* 2011; 63(2): 437-59.
6. Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. *Am J Health Syst Pharm.* 2002; 59(21): 2061-9.
7. Man M, Farmen M, Dumaul C, Teng CH, Moser B, Irie S et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. *J Clin Pharmacol.* 2010; 50(8): 929-40.
8. Koo SH, Lee EJ. Pharmacogenetics approach to therapeutics. *Clin Exp Pharmacol Physiol.* 2006; 33(5-6): 525-32.
9. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. *Clin Pharmacol Ther.* 2008; 84(3): 417-23.
10. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology--with emphasis on cytochrome P450. *Toxicol Sci.* 2011; 120(1): 1-13.
11. Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. *J Pharm Sci.* 1997; 86(12): 1328-33.
12. Munoz C, Hilgenberg C. Ethnopharmacology. *Am J Nurs.* 2005; 105(8): 40-8.
13. International Conference on Harmonisation; guidance on ethnic factors in the acceptability of foreign clinical data; availability--FDA. Notice. *Fed Regist.* 1998; 63(111): 31790-6.
14. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. *Annu Rev Pharmacol Toxicol.* 2001; 41: 815-50.
15. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ et al. The importance of race and ethnic background in biomedical research and clinical practice. *N Engl J Med.* 2003; 348(12): 1170-5.
16. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. *Clin Pharmacokinet.* 2006; 45(10): 957-64.
17. Karlsson AO, Wallerstrom T, Gotherstrom A, Holmlund G. Y-chromosome diversity in Sweden - a long-time perspective. *Eur J Hum Genet.* 2006; 14(8): 963-70.
18. Dupanloup I, Bertorelle G, Chikhi L, Barbujani G. Estimating the impact of prehistoric admixture on the genome of Europeans. *Mol Biol Evol.* 2004; 21(7): 1361-72.
19. Corovic V. [Penetration of Slavs in the Balkans]. In: Janicijevic S, Mijovic S, eds. [Illustrated History of the Serbs]. Beograd: Narodna knjiga-Alfa 2005. p.5-23. Serbian.

20. Pericic M, Lauc LB, Klaric IM, Roots S, Janicijevic B, Rudan I et al. High-resolution phylogenetic analysis of southeastern Europe traces major episodes of paternal gene flow among Slavic populations. *Mol Biol Evol.* 2005; 22(10): 1964-75.
21. Regueiro M, Rivera L, Damnjanovic T, Lukovic L, Milasin J, Herrera RJ. High levels of paleolithic Y-chromosome lineages characterize Serbia. *Gene.* 2012; DOI:10.1016/j.gene.2012.01.030
22. Nei M, Roychoudhury AK. Evolutionary relationships of human populations on a global scale. *Mol Biol Evol.* 1993; 10(5): 927-43.
23. Abdulla MA, Ahmed I, Assawamakin A, Bhak J, Brahmachari SK, Calacal GC et al. Mapping human genetic diversity in Asia. *Science.* 2009; 326(5959): 1541-5.
24. Belle DJ, Singh H. Genetic factors in drug metabolism. *Am Fam Physician.* 2008; 77(11): 1553-60.
25. Glubb DM, Innocenti F. Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters. *Wiley Interdiscip Rev Syst Biol Med.* 2011; 3(3): 299-313.
26. Atkinson AJ, Abernethy DR, Daniels CE, Dedrick RL, Markey SP. Principles of clinical pharmacology. Burlington, MA: Elsevier Inc; 2007. p.545.
27. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. *Eur J Clin Pharmacol.* 2007; 63(6): 537-46.
28. Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. *Free Radic Biol Med.* 2008; 44(5): 723-38.
29. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. *Clin Pharmacokinet.* 1998; 35(5): 361-90.
30. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. *Ther Drug Monit.* 2007; 29(6): 687-710.
31. Heckman MA, Sherry K, Gonzalez de Mejia E. Energy drinks: an assessment of their market size, consumer demographics, ingredient profile, functionality, and regulations in the United States. *Compr Rev Food Sci F.* 2010; 9: 303-17.
32. Chou T. Wake up and smell the coffee. Caffeine, coffee, and the medical consequences. *West J Med.* 1992; 157(5): 544-53.
33. Fredholm BB. Notes on the history of caffeine use. *Handb Exp Pharmacol.* 2011; 200: 1-9.
34. George SE, Ramalakshmi K, Mohan Rao LJ. A perception on health benefits of coffee. *Crit Rev Food Sci Nutr.* 2008; 48(5): 464-86.
35. Yang A, Palmer AA, de Wit H. Genetics of caffeine consumption and responses to caffeine. *Psychopharmacology (Berl).* 2010; 211(3): 245-57.
36. Mandel HG. Update on caffeine consumption, disposition and action. *Food Chem Toxicol.* 2002; 40(9): 1231-4.
37. Butt MS, Sultan MT. Coffee and its consumption: benefits and risks. *Crit Rev Food Sci Nutr.* 2011; 51(4): 363-73.
38. Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. *Pharmacol Rep.* 2008; 60(6): 789-97.
39. Glade MJ. Caffeine-not just a stimulant. *Nutrition.* 2010; 26(10): 932-8.
40. Ferre S. An update on the mechanisms of the psychostimulant effects of caffeine. *J Neurochem.* 2008; 105(4): 1067-79.

41. Amin N, Byrne E, Johnson J, Chenevix-Trench G, Walter S, Nolte IM et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. *Mol Psychiatry*. 2011; DOI:10.1038/mp.2011.101
42. Heckman MA, Weil J, Gonzalez de Mejia E. Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. *J Food Sci*. 2010; 75(3): R77-87.
43. Benowitz NL. Clinical pharmacology of caffeine. *Annu Rev Med*. 1990; 41: 277-88.
44. Sweetman SC, ed. *Martindale: The complete drug reference 36*. [CD-ROM]. London: Pharmaceutical Press; 2009.
45. Miners JO, Birkett DJ. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. *Gen Pharmacol*. 1996; 27(2): 245-9.
46. Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. *Pharmacogenetics*. 2000; 10(3): 187-216.
47. Chen Y, Xiao P, Ou-Yang DS, Fan L, Guo D, Wang YN et al. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. *Clin Exp Pharmacol Physiol*. 2009; 36(8): 828-33.
48. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. *Drug Metab Rev*. 2010; 42(2): 268–354.
49. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. *Biomark Med*. 2011; 5(6): 795-806.
50. Tomaszewski P, Kubiak-Tomaszewska G, Pachecka J. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. *Acta Pol Pharm*. 2008; 65(3): 307-18.
51. Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. *Aaps J*. 2009; 11(3): 481-94.
52. Thorn CF, Aklillu E, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP1A2. *Pharmacogenet Genomics*. 2012; 22(1): 73-7.
53. Wooding SP, Watkins WS, Bamshad MJ, Dunn DM, Weiss RB, Jorde LB. DNA sequence variation in a 3.7-kb noncoding sequence 5' of the CYP1A2 gene: implications for human population history and natural selection. *Am J Hum Genet*. 2002; 71(3): 528-42.
54. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. *Br J Clin Pharmacol*. 1999; 47(4): 445-9.
55. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. *J Biochem*. 1999; 125(4): 803-8.
56. Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR et al. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. *Br J Clin Pharmacol*. 2002; 54(5): 540-3.
57. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression:

- characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. *Mol Pharmacol.* 2003; 64(3): 659-69.
58. Rasmussen BB, Brix TH, Kyvik KO, Brosen K. The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. *Pharmacogenetics.* 2002; 12(6): 473-8.
 59. Fontana RJ, Lown KS, Paine MF, Fortlage L, Santella RM, Felton JS et al. Effects of a char-grilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. *Gastroenterology.* 1999; 117(1): 89-98.
 60. Parker AC, Pritchard P, Preston T, Choonara I. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. *Br J Clin Pharmacol.* 1998; 45(2): 176-8.
 61. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. *Br J Clin Pharmacol.* 1995; 39(2): 151-9.
 62. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. *Clin Pharmacol Ther.* 1992; 52(6): 643-58.
 63. Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. *Pharmacogenetics.* 1999; 9(2): 131-44.
 64. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. *Clin Pharmacol Ther.* 1991; 50(5 Pt 1): 508-19.
 65. Masimirembwa CM, Beke M, Hasler JA, Tang BK, Kalow W. Low CYP1A2 activity in rural Shona children of Zimbabwe. *Clin Pharmacol Ther.* 1995; 57(1): 25-31.
 66. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. *Cancer Epidemiol Biomarkers Prev.* 1994; 3(5): 413-21.
 67. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. *Pharmacogenetics.* 1994; 4(3): 109-16.
 68. Spigset O, Hagg S, Soderstrom E, Dahlqvist R. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? *Pharmacogenetics.* 1999; 9(3): 409-12.
 69. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. *Drug Metab Rev.* 2009; 41(2): 89-295.
 70. Pelkonen O, Rautio A, Raunio H, Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. *Toxicology.* 2000; 144(1-3): 139-47.
 71. Raunio H, Rautio A, Gullsten H, Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. *Br J Clin Pharmacol.* 2001; 52(4): 357-63.
 72. Sinues B, Fanlo A, Mayayo E, Carcas C, Vicente J, Arenaz I et al. CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. *Hum Exp Toxicol.* 2008; 27(367-72).
 73. Di YM, Chow VDW, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. *Curr Drug Metab.* 2009; 10(6): 1-27.

74. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. *Drug Metab Dispos.* 2001; 29(2): 91-5.
75. Bloom J, Hinrichs AL, Wang JC, von Weyarn LB, Kharasch ED, Bierut LJ et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. *Pharmacogenet Genom.* 2011; 21: 403-16.
76. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. *Mol Pharmacol.* 2000; 58(4): 747-55.
77. Xu C, Rao YS, Xu B, Hoffmann E, Jones J, Sellers EM et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. *Biochem Biophys Res Commun.* 2001; 290: 318-24.
78. Runkel M, Bourian M, Tegtmeier M, Legrum W. The character of inhibition of the metabolism of 1,2-benzopyrone (coumarin) by grapefruit juice in human. *Eur J Clin Pharmacol.* 1997; 53(3-4): 265-9.
79. Muscat JE, Pittman B, Kleinman W, Lazarus P, Stellman SD, Richie JP, Jr. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers. *Biochem Pharmacol.* 2008; 76(7): 929-37.
80. Benowitz NL, Jacob III P. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. *Clin Pharmacol Ther* 2000; 67: 653-9.
81. Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. *Eur J Clin Pharmacol.* 2010; 66: 571-8.
82. Benowitz NL, Lessov-Schlaggar CN, Swan GE, and, Jacob III P. Female sex and oral contraceptive use accelerate nicotine metabolism. *Clin Pharmacol Ther* 2006; 79: 480-8.
83. Mwenifumbo JC, Sellers EM, Tyndale RF. Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking. *Drug Alcohol Depen* 2007; 89: 24-33.
84. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asproдини EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. *Biomed Chromatogr* 2007; 21: 190-200.
85. Krul C, Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl.* 1998; 709(1): 27-34.
86. Benowitz NL, Swan GE, Jacob III P, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. *Clin Pharmacol Ther* 2006; 80: 457-67.
87. Nowell S, Sweeney C, Hammons G, Kadlubar FF, Lang NP. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2002; 11(4): 377-83.
88. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. *PLoS One.* 2011; 6(4): e18507.
89. Meisel P. Arylamine N-acetyltransferases and drug response. *Pharmacogenomics.* 2002; 3(3): 349-66.

90. Westwood IM, Kawamura A, Fullam E, Russell AJ, Davies SG, Sim E. Structure and mechanism of arylamine N-acetyltransferases. *Curr Top Med Chem*. 2006; 6(15): 1641-54.
91. Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, Sorgel F, Fuhr U. Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? *Eur J Clin Pharmacol*. 2009; 65(4): 411-7.
92. Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. *J Toxicol Environ Health B Crit Rev*. 2009; 12(5-6): 440-72.
93. Talbot J, Magno LA, Santana CV, Sousa SM, Melo PR, Correa RX et al. Interethnic diversity of NAT2 polymorphisms in Brazilian admixed populations. *BMC Genet*. 2010; 11: 87.
94. Butcher NJ, Boukouvala S, Sim E, Minchin RF. Pharmacogenetics of the arylamine N-acetyltransferases. *Pharmacogenomics J*. 2002; 2(1): 30-42.
95. Pompeo F, Brooke E, Kawamura A, Mushtaq A, Sim E. The pharmacogenetics of NAT: structural aspects. *Pharmacogenomics*. 2002; 3(1): 19-30.
96. García-Martín E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. *Curr Drug Metab*. 2008; 9: 487-97.
97. Kang TS, Jin SK, Lee JE, Woo SW, Roh J. Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups. *J Clin Pharm Ther*. 2009; 34: 709-18.
98. Le Marchand L, Sivaraman L, Franke AA, Custer LJ, Wilkens LR, Lau AF et al. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? *Cancer Epidemiol Biomarkers Prev*. 1996; 5(6): 449-55.
99. Kashuba AD, Bertino JS, Jr., Kearns GL, Leeder JS, James AW, Gotschall R et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. *Clin Pharmacol Ther*. 1998; 63(5): 540-51.
100. Pritsos CA. Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. *Chem Biol Interact*. 2000; 129(1-2): 195-208.
101. Kudo M, Moteki T, Sasaki T, Konno Y, Ujiie S, Onose A et al. Functional characterization of human xanthine oxidase allelic variants. *Pharmacogenet Genomics*. 2008; 18(3): 243-51.
102. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. *Clin Pharmacol Ther*. 1991; 50(6): 663-72.
103. Streetman D, Bleakley J, Kim J, Nafziger A, Leeder J, Gaedigk A et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". *Clin Pharmacol Ther*. 2000; 68: 375-83.
104. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? *Free Radic Biol Med*. 2002; 33(6): 774-97.
105. Garattini E, Mendel R, Romao MJ, Wright R, Terao M. Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. *Biochem J*. 2003; 372(Pt 1): 15-32.
106. Kitamura S, Sugihara K, Ohta S. Drug-metabolizing ability of molybdenum hydroxylases. *Drug Metab Pharmacokinet*. 2006; 21(2): 83-98.

107. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. *Pharmacol Rev.* 2006; 58(1): 87-114.
108. Chung WG, Kang JH, Park CS, Cho MH, Cha YN. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. *Clin Pharmacol Ther.* 2000; 67(3): 258-66.
109. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. *Clin Pharmacol Ther.* 1994; 55(3): 293-304.
110. Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M. Xanthine oxidase activity is influenced by environmental factors in Ethiopians. *Eur J Clin Pharmacol.* 2003; 59(7): 533-6.
111. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. *Circulation.* 2003; 107(3): 416-21.
112. Martin HM, Hancock JT, Salisbury V, Harrison R. Role of xanthine oxidoreductase as an antimicrobial agent. *Infect Immun.* 2004; 72(9): 4933-9.
113. Ghio AJ, Kennedy TP, Stonehuerner J, Carter JD, Skinner KA, Parks DA et al. Iron regulates xanthine oxidase activity in the lung. *Am J Physiol Lung Cell Mol Physiol.* 2002; 283(3): L563-72.
114. Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. *J Pharm Pharmacol.* 2011; 63(9): 1161-8.
115. Saaksjarvi K, Knekt P, Mannisto S, Heliövaara M. Self-administered questionnaire is a reliable measure of coffee consumption. *J Epidemiol.* 2010; 20(5): 363-9.
116. Lindroos K, Sigurdsson S, Johansson K, Ronnblom L, Syvanen AC. Multiplex SNP genotyping in pooled DNA samples by a four-colour microarray system. *Nucleic Acids Res.* 2002; 30(14): e70.
117. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T. Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. *Jpn J Cancer Res.* 1999; 90(9): 899-902.
118. Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bernal ML et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. *FEBS Lett.* 1999; 448(1): 105-10.
119. Oscarson M, McLellan RA, Gullsten H, Agundez JA, Benitez J, Rautio A et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. *FEBS Lett.* 1999; 460(2): 321-7.
120. Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. *Br J Clin Pharmacol.* 2002; 54(5): 511-7.
121. Anitha A, Banerjee M. Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. *Int J Mol Med.* 2003; 11(1): 125-31.
122. Doll MA, Hein DW. Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1. *Analytical Biochemistry.* 2002; 301: 328-32.
123. Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. *Pharmacogenetics.* 1999; 9(1): 103-11.

124. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. *Clin Pharmacol Ther.* 2007; 81(2): 270-83.
125. Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. *Ther Drug Monit.* 2000; 22(4): 409-17.
126. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. *Pharmacogenetics.* 1996; 6(2): 121-49.
127. Wang D, Jiang Z, Shen Z, Wang H, Wang B, Shou W et al. Functional evaluation of genetic and environmental regulators of p450 mRNA levels. *PLoS One.* 2011; 6(10): e24900.
128. Kawajiri K, Fujii-Kuriyama Y. Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor. *Arch Biochem Biophys.* 2007; 464(2): 207-12.
129. Murray M. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. *Curr Drug Metab.* 2000; 1(1): 67-84.
130. Del Bubba M, Zanieri L, Galvan P, Donzelli GP, Checchini L, Lepri L. Determination of polycyclic aromatic hydrocarbons (PAHs) and total fats in human milk. *Ann Chim.* 2005; 95(9-10): 629-41.
131. Toxicological profile for Polycyclic Aromatic Hydrocarbons In Edition U.S. Department of Health and Human Services. Agency for Toxic Substances and Disease Registry. Atlanta, Georgia 1995.
132. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. *Clin Pharmacol Ther.* 2011; 90(1): 117-25.
133. Ayalogu EO, Snelling J, Lewis DF, Talwar S, Clifford MN, Ioannides C. Induction of hepatic CYP1A2 by the oral administration of caffeine to rats: lack of association with the Ah locus. *Biochim Biophys Acta.* 1995; 1272(2): 89-94.
134. Kalthoff S, Ehmer U, Freiberg N, Manns MP, Strassburg CP. Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. *Gastroenterology.* 2010; 139(5): 1699-710.
135. Houessou JK, Maloug S, Leveque AS, Delteil C, Heyd B, Camel V. Effect of roasting conditions on the polycyclic aromatic hydrocarbon content in ground Arabica coffee and coffee brew. *J Agric Food Chem.* 2007; 55(23): 9719-26.
136. Orecchio S, Ciotti VP, Culotta L. Polycyclic aromatic hydrocarbons (PAHs) in coffee brew samples: analytical method by GC-MS, profile, levels and sources. *Food Chem Toxicol.* 2009; 47(4): 819-26.
137. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. *Br J Clin Pharmacol.* 2003; 55(1): 68-76.
138. Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. *Pharmacogenomics.* 2009; 10(5): 769-78.

139. Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E. Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. *Mutat Res.* 2005; 587(1-2): 59-66.
140. Shimoda K, Someya T, Morita S, Hirokane G, Yokono A, Takahashi S et al. Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5'-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* 2002; 26(2): 261-5.
141. Takata K, Saruwatari J, Nakada N, Nakagawa M, Fukuda K, Tanaka F et al. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. *Eur J Clin Pharmacol.* 2006; 62(1): 23-8.
142. Yang LP, Zhou ZW, Chen XW, Li CG, Sneed KB, Liang J et al. Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2. *Xenobiotica.* 2011; 42(3): 238-55.
143. Kang AY, Young LR, Dingfelder C, Peterson S. Effects of furanocoumarins from apiaceous vegetables on the catalytic activity of recombinant human cytochrome P-450 1A2. *Protein J.* 2011; 30(7): 447-56.
144. Schoedel KA, Hoffmann EH, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in *CYP2A6* and association of genetically slow nicotine metabolism and smoking in adult Caucasians. *Pharmacogenetics* 2004; 14: 615–26.
145. Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. *CYP2A6* genotype, phenotype, and the use of nicotine metabolites as biomarkers during *Ad libitum* smoking. *Cancer Epidemiol Biomarkers Prev* 2006; 15(10): 1812–9.
146. Kwon J-T, Nakajima M, Chai S, Yom Y-K, Kim H-K, Yamazaki H et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. *Pharmacogenetics.* 2001; 11: 317-23.
147. Haberl M, Anwald B, Klein K, Weil R, Fuss C, Gepdiremen A et al. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. *Pharmacogenet Genomics.* 2005; 15(9): 609-24.
148. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. *Clin Pharmacol Ther.* 2006; 80: 282-97.
149. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T. Effects of polymorphism in promoter region of human *CYP2A6* gene (*CYP2A6*9*) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. *Clin Pharmacol Ther* 2003; 74(69-76).
150. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. *Clin Pharmacol Ther.* 2001; 69(1): 72-8.
151. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob P, 3rd. Ethnic differences in N-glucuronidation of nicotine and cotinine. *J Pharmacol Exp Ther.* 1999; 291(3): 1196-203.
152. Kandel DB, Hu M-C, Schaffran C, Udry JR, Benowitz NL. Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. *Am J Epidemiol* 2007; 165: 901–10.
153. Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. *Adv Drug Deliv Rev.* 2002; 54(10): 1245-56.

154. Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. *Clin Pharmacol Ther.* 2006; 80: 319-30.
155. Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T et al. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. *Drug Metab Pharmacokinet.* 2006; 21(6): 475-84.
156. Kadlubar S, Anderson JP, Sweeney C, Gross MD, Lang NP, Kadlubar FF et al. Phenotypic CYP2A6 variation and the risk of pancreatic cancer. *Jop.* 2009; 10(3): 263-70.
157. Xu P, Huang SL, Zhu RH, Han XM, Zhou HH. Phenotypic polymorphism of CYP2A6 activity in a Chinese population. *Eur J Clin Pharmacol.* 2002; 58: 333-7.
158. Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. *Clin Pharmacol Ther.* 2004; 76(6): 618-27.
159. Klotz U. Pharmacokinetics and drug metabolism in the elderly. *Drug Metab Rev.* 2009; 41(2): 67-76.
160. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. *Best Pract Res Clin Gastroenterol.* 2001; 15(6): 897-918.
161. Kinirons MT, O'Mahony MS. Drug metabolism and ageing. *Br J Clin Pharmacol.* 2004; 57(5): 540-4.
162. Benedetti MS, Whomsley R, Canning M. Drug metabolism in the paediatric population and in the elderly. *Drug Discov Today.* 2007; 12(15-16): 599-610.
163. Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. *Drug Metab Dispos.* 1987; 15(2): 237-49.
164. Grant DM, Campbell ME, Tang BK, Kalow W. Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies. *Biochem Pharmacol.* 1987; 36(8): 1251-60.
165. Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. *Cancer Epidemiol Biomarkers Prev.* 1997; 6(4): 225-31.
166. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. *Am J Hum Genet.* 1995; 57(3): 581-92.
167. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. *Cancer Epidemiol Biomarkers Prev.* 1999; 8(8): 683-92.
168. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frötschl R, Köpke K et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. *Eur J Clin Pharmacol.* 2003; 59: 303-12.
169. Straka RJ, Burkhardt T, Lang NP, Hadsall KZ, Tsai MY. Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects. *J Clin Pharmacol.* 2006; 46: 802-11.

170. Lee S, Lee K, Ki C, Kwon OJ, Kim HJ, Chung MP et al. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. *Clin Chem.* 2002; 48(5): 775-7.
171. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. *Pharmacogenetics.* 2002; 12(5): 375-83.
172. Hein DW. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. *Expert Opin Drug Metab Toxicol.* 2009; 5(4): 353-66.
173. Walraven JM, Trent JO, Hein DW. Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1. *Drug Metab Rev.* 2008; 40(1): 169-84.
174. Zhu Y, Hein DW. Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. *Pharmacogenomics J.* 2008; 8(5): 339-48.
175. Saruwatari J, Nakagawa K, Shindo J, Tajiri T, Fujieda M, Yamazaki H et al. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. *Clin Pharmacol Ther.* 2002; 72(2): 200-8.
176. Evans DA. N-acetyltransferase. *Pharmacol Ther.* 1989; 42(2): 157-234.
177. Rihs HP, John A, Scherenberg M, Seidel A, Bruning T. Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. *Clin Chim Acta.* 2007; 376(1-2): 240-3.
178. Jiao L, Doll MA, Hein DW, Bondy ML, Hassan MM, Hixson JE et al. Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer. *Cancer Epidemiol Biomarkers Prev.* 2007; 16(11): 2379-86.
179. Soucek P, Skjelbred CF, Svendsen M, Kristensen T, Kure EH, Kristensen VN. Single-track sequencing for genotyping of multiple SNPs in the N-acetyltransferase 1 (NAT1) gene. *BMC Biotechnol.* 2004; 4: 28.
180. Ghotbi R, Gomez A, Milani L, Tybring G, Syvanen AC, Bertilsson L et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. *Pharmacogenomics J.* 2009; 9(3): 208-17.
181. Rasmussen BB, Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. *Ther Drug Monit.* 1996; 18(3): 254-62.
182. Brown AM, Benboubetra M, Ellison M, Powell D, Reckless JD, Harrison R. Molecular activation-deactivation of xanthine oxidase in human milk. *Biochim Biophys Acta.* 1995; 1245(2): 248-54.